Get the Stockscreener App
18.34
4.74%
0.83
After Hours:
18.34
Arcturus Therapeutics Holdings Inc stock is traded at $18.34, with a volume of 199.52K.
It is up +4.74% in the last 24 hours and down -4.08% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
See More
Previous Close:
$17.51
Open:
$17.67
24h Volume:
199.52K
Relative Volume:
0.53
Market Cap:
$496.78M
Revenue:
$157.75M
Net Income/Loss:
$-29.73M
P/E Ratio:
6.1338
EPS:
2.99
Net Cash Flow:
$-21.00M
1W Performance:
+8.46%
1M Performance:
-4.08%
6M Performance:
-50.05%
1Y Performance:
-24.34%
1-Day Range:
$17.55
$18.61
1-Week Range:
$16.83
$18.61
52-Week Range:
$14.93
$45.00
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
18.34 | 496.78M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Arcturus Therapeutics to Attend Upcoming Investor Conferences - BioSpace
Arcturus Therapeutics to Present at Major Healthcare Investor Conferences in December | ARCT Stock News - StockTitan
GSA Capital Partners LLP Has $219,000 Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference - Yahoo Finance
Sumitomo Mitsui Trust Group Inc. Buys 712,650 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Avian Flu: FDA Authorizes Self-Replicating Vaccine Trial to Bill Gates-Backed Company, "Study Can Proceed" - presskit.it
Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data (NASDAQ:ARCT) - Seeking Alpha
Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production | ARCT Stock News - StockTitan
Arcturus gains IND clearance for H5N1 influenza sa-RNA vaccine candidate - BioWorld Online
Possible Signal As Arcturus Therapeutics Holdings Insiders Sell US$1.6m In Stock - Simply Wall St
Another Avian Influenza mRNA Vaccine Candidate Advances - Precision Vaccinations
Arcturus Therapeutics Holdings Inc. Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial - Marketscreener.com
What is HC Wainwright's Estimate for ARCT FY2028 Earnings? - MarketBeat
Arcturus Therapeutics’ (ARCT) Buy Rating Reiterated at HC Wainwright - Defense World
Earnings call: Arcturus Therapeutics reported a net loss of $6.9 million - Investing.com Australia
Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2024 Earnings Call Transcript - Insider Monkey
Nikko Asset Management Americas, Inc. Expands Stake in Arcturus Therapeutics Holdings Inc. - GuruFocus.com
Arcturus Therapeutics (NASDAQ:ARCT) Receives "Buy" Rating from HC Wainwright - MarketBeat
ARK Investment Management LLC Has $48.77 Million Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Average Target Price from Brokerages - Defense World
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call - GuruFocus.com
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ... - Yahoo Finance UK
Arcturus Therapeutics Reports Q3 2024 Financial Results and Milestones - TipRanks
Arcturus Therapeutics Holdings Inc earnings beat by $0.31, revenue fell short of estimates - Investing.com
ARCTArcturus Therapeutics Holdings Inc. Latest Stock News & Market Updates - StockTitan
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Arcturus Therapeutics: Q3 Earnings Snapshot - Marketscreener.com
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress - Business Wire
Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect - MSN
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Repor - GuruFocus.com
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Sumitomo Mitsui Trust Group, Inc. Expands Investment in Arcturus Therapeutics Holdings Inc. - GuruFocus.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Empire Life Investments Inc. Purchases New Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics (ARCT) Scheduled to Post Earnings on Thursday - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below Two Hundred Day Moving AverageHere's Why - MarketBeat
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024 - Business Wire
Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Arcturus falls after detailed Phase 1 data for cystic fibrosis therapy - MSN
Leerink Partners Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Outperform Recommendation - MSN
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 6.1%What's Next? - MarketBeat
Investing in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gain - Yahoo Finance
8,235 Shares in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Acquired by SG Americas Securities LLC - Defense World
A slow start for self-amplifying mRNA vaccines - Yahoo Finance
Vontobel Holding Ltd. Trims Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 5.8% Following Insider Selling - MarketBeat
AQR Capital Management LLC Has $285,000 Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Insider Sale at Arcturus Therapeutics Holdings Inc (ARCT) - GuruFocus.com
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):